Faja milonítica El Cortijo: puesta en valor de su patrimonio geominero y propuesta de un nuevo sitio de interés geológico en Tandil, Buenos Aires

El basamento del Sistema de Tandilia reúne a las rocas más antiguas de la Argentina, las cuales guardan una valiosa información de los procesos geológicos ocurridos hace aproximadamente 2.200 Ma. Entre estas rocas ígneo-metamórficas (Complejo Buenos Aires) se encuentran las que integran la Formación El Cortijo, que contrastan notoriamente con el resto por sus características mineralógicas, metamórficas y estructurales. Esta Formación está constituida por rocas típicas de una cuenca oceánica desarrollada durante el lapso Neoarqueano - Paleoproterozoico, fuertemente milonitizadas. Aflora en las cercanías de la ciudad de Tandil, a lo largo de una faja de 3 kilómetros con rumbo este-oeste (aquí denominada Faja milonítica El Cortijo), a la que se accede por la Ruta Nacional 226. Tandil es una ciudad reconocida por su origen minero, actualmente con una fuerte impronta turística y una infraestructura óptima para ofrecer diversos circuitos geomineros. Esta contribución tiene como objetivo presentar un nuevo sitio de interés geológico en Tandil, que junto con los otros circuitos geoturísticos urbanos, manifieste el valor geológico de la región. Esto conduciría a su protección y podría impulsar la creación de un futuro Parque Geológico, producto de la integración de todos los geositios conocidos además del aquí propuesto. El trabajo realizado incluyó un relevamiento del área mediante imágenes satelitales y actividades de campo que permitieron seleccionar un conjunto de canteras labradas en la faja milonítica que constituye el geositio propuesto. Este sector de la provincia de Buenos Aires reúne todos los atributos necesarios para establecer un sitio de interés geológico como el sugerido, considerando sus riquezas paisajísticas y geológicas relacionadas con la evolución geológica y tectónica del basamento de Tandilia

Large geographic and temporal extensions of the Río de la Plata Craton, South America, and its metacratonic eastern margin

Integration of existing isotopic and geological data allows a reconsideration of the distribution and age of the Río de la Plata Craton within South America. The reinterpretation increases the area of the craton to about 2,400,000 km2 with implications for the tectonic map of South America and for global reconstruction of palaeocontinents. Four areas previously considered as separate cratons (Luís Alves, Curitiba, Tebicuary, and Paranapanema) are interpreted as part of the same Río de la Plata Craton. The craton is organized into six provinces and domains: Buenos Aires–Piedra Alta, Taquarembó, Tebicuary, Luís Alves, Encantadas, and Nico Pérez. The term ‘Transplatense’ is proposed to replace ‘Trans-Amazonian’ for Rhyacian events that occurred within the Río de la Plata Craton. The craton is formed not only by dominant Rhyacian rocks and local Archaean rocks, but also by Statherian and Mesoproterozoic rocks. The domains are all partially to totally covered by Phanerozoic basins (Paraná, Chacoparanense, Claromecó, Salado, Balcarce, and Colorado) which makes their investigation difficult. The Ediacaran–Cambrian collisions of the Brasilian orogen generated tectonic mixtures of orogenic and cratonic zones. This is more evident in the eastern margin of the craton, which behaved as a metacraton

TRF2 positively regulates SULF2 expression increasing VEGF - A release and activity in tumor microenvironment

The telomeric protein TRF2 is overexpressed in several human malignancies and contributes to tumorigenesis even though the molecular mechanism is not completely understood. By using a high-throughput approach based on the multiplexed Luminex X-MAP technology, we demonstrated that TRF2 dramatically affects VEGF-A level in the secretome of cancer cells, promoting endothelial cell-differentiation and angiogenesis. The pro-angiogenic effect of TRF2 is independent from its role in telomere capping. Instead, TRF2 binding to a distal regulatory element promotes the expression of SULF2, an endoglucosamine-6-sulfatase that impairs the VEGF-A association to the plasma membrane by inducing post-synthetic modification of heparan sulfate proteoglycans (HSPGs). Finally, we addressed the clinical relevance of our findings showing that TRF2/SULF2 expression is a worse prognostic biomarker in colorectal cancer (CRC) patients.The telomeric protein TRF2 is overexpressed in several human malignancies and contributes to tumorigenesis even though the molecular mechanism is not completely understood. By using a high-throughput approach based on the multiplexed Luminex X-MAP technology, we demonstrated that TRF2 dramatically affects VEGF-A level in the secretome of cancer cells, promoting endothelial cell-differentiation and angiogenesis. The pro-angiogenic effect of TRF2 is independent from its role in telomere capping. Instead, TRF2 binding to a distal regulatory element promotes the expression of SULF2, an endoglucosamine-6-sulfatase that impairs the VEGF-A association to the plasma membrane by inducing post-synthetic modification of heparan sulfate proteoglycans (HSPGs). Finally, we addressed the clinical relevance of our findings showing that TRF2/SULF2 expression is a worse prognostic biomarker in colorectal cancer (CRC) patients

RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies

Objective: The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID-19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418) to retrospectively investigate the relationship between RAAS inhibitors and COVID-19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies. Methods: We analyzed 4,069 unselected patients with laboratory-confirmed SARS-CoV-2 infection and hospitalized in 34 clinical centers in Italy from February 19, 2020 to May 23, 2020. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received angiotensin-converting\u2013enzyme inhibitors (ACE-I) or angiotensin-receptor blockers (ARB) with patients who did not. Articles for the meta-analysis were retrieved until July 13th, 2020 by searching in web-based libraries, and data were combined using the general variance-based method. Results: Out of 4,069 COVID-19 patients, 13.5% and 13.3% received ACE-I or ARB, respectively. Use of neither ACE-I nor ARB was associated with mortality (multivariable hazard ratio (HR) adjusted also for COVID-19 treatments: 0.96, 95% confidence interval 0.77-1.20 and HR=0.89, 0.67-1.19 for ACE-I and ARB, respectively). Findings were similar restricting the analysis to hypertensive (N=2,057) patients (HR=1.00, 0.78-1.26 and HR=0.88, 0.65-1.20) or when ACE-I or ARB were considered as a single group. Results from the meta-analysis (19 studies, 29,057 COVID-19 adult patients, 9,700 with hypertension) confirmed the absence of association. Conclusions: In this observational study and meta-analysis of the literature, ACE-I or ARB use was not associated with severity or in-hospital mortality in COVID-19 patients